Dose-dependent perinatal risks of clomiphene citrate in US IVF cycles: a national cohort study, 2004-2021.
Higher clomiphene citrate doses linked to greater spontaneous abortion risk in IVF
Dose-dependent perinatal risks of clomiphene citrate in US IVF cycles: a national cohort study, 2004-2021.
The relationship between clomiphene citrate (clomiphene citrate) dosing regimens and adverse reproductive outcomes has not been fully elucidated, both with and without use of in vitro fertilisation (IVF).
We aimed to study the association between cumulative clomiphene citrate dose and perinatal outcomes among fresh autologous IVF cycles.
We included all fresh autologous IVF embryo transfer cycles performed in the US fertility clinics during 2004-2021 using clomiphene citrate for ovulation induction.
higher clomiphene doses raised the risk of miscarriage after ivf
Among fresh autologous embryo transfer cycles using clomiphene citrate, 21.3% used <500 mg, 67.8% used 500-749 mg, 7.2% used 750-999 mg and 3.7% used ≥1000 mg.
The ≥1000 mg group had a three-fold higher rate of stillbirth than the <500 mg group, but these estimates were imprecise (0.7% vs 0.2%; aRR, 3.31; 95% CI 0.88 to 12.40).
Multiple birth risk was significantly higher among all clomiphene citrate dosage categories compared with the <500 mg group.
Our findings extend previous findings on the association between clomiphene citrate exposure and adverse perinatal outcomes by demonstrating a dose-dependent relationship.